Lotilaner ophthalmic solution receives approval for Demodex blepharitis from NMPA in China

The National Medical Products Administration (NMPA) of China has approved lotilaner ophthalmic solution 0.25% (TP-03), marketed in the United States as Xdemvy, for the treatment of Demodex blepharitis, according to a March 2026 announcement from Tarsus Pharmaceuticals. The decision marks the first regulatory approval for a therapy targeting the underlying mite infestation in this condition in the Greater China region, where disease prevalence is substantial.

Demodex blepharitis is increasingly recognized as a common yet underdiagnosed contributor to chronic eyelid inflammation, with implications for ocular surface disease and surgical outcomes. The availability of a targeted antiparasitic therapy in China may represent a clinically meaningful addition to management options that have historically relied on lid hygiene and off-label treatments with inconsistent efficacy.

Regulatory and development overview

The approval was granted based on clinical data previously submitted by Tarsus and its regional partner, Grand Pharmaceutical Group Limited, which holds commercialization rights in Greater China. Although the company did not disclose specific trial data in the announcement, the US Food and Drug Administration (FDA) approval of lotilaner ophthalmic solution in 2023 was supported by 2 randomized, vehicle-controlled phase 3 trials—SATURN-1 and SATURN-2.¹

In these studies, lotilaner demonstrated statistically significant improvements in collarette cure (defined as ≤2 collarettes per lid) and mite eradication compared with vehicle at day 43. In SATURN-1, 44% of treated patients achieved collarette cure versus 7% with vehicle (P < .0001), while mite eradication rates were 68% versus 17%, respectively.¹ Similar results were observed in SATURN-2, reinforcing reproducibility across study populations.²

Safety findings across trials indicated that the therapy was generally well tolerated, with instillation site discomfort as the most commonly reported adverse event.¹^,² No significant ocular safety signals were identified in the short-term studies.

Clinical context and unmet need

Demodex blepharitis is caused by infestation of Demodex folliculorum mites within eyelash follicles and sebaceous glands. Epidemiologic studies suggest that Demodex may be present in a majority of patients with blepharitis, particularly in older populations.³ Clinical signs include cylindrical dandruff (collarettes), lid margin erythema, and ocular irritation.

Management has traditionally consisted of mechanical lid hygiene and tea tree oil–based regimens, which may reduce mite burden but are often associated with poor tolerability and variable adherence.⁴ No FDA-approved therapies were available prior to lotilaner’s US approval, underscoring the significance of a pharmacologic option with demonstrated efficacy against the underlying parasite.

The burden of disease is not limited to symptoms; Demodex blepharitis has been associated with exacerbation of dry eye disease and may complicate preoperative optimization for cataract and refractive surgery.⁵

Mechanism of Action and Drug Background

Lotilaner is a gamma-aminobutyric acid (GABA)-gated chloride channel inhibitor that selectively targets invertebrate nervous systems, leading to paralysis and death of mites.⁶ The compound is derived from the isoxazoline class, which has been widely used in veterinary medicine for ectoparasite control.

Xdemvy (lotilaner ophthalmic solution 0.25%) was approved by the FDA in July 2023 for the treatment of Demodex blepharitis, becoming the first agent specifically indicated for this condition.⁷ The approval was based on the SATURN clinical program and represented a shift toward mechanism-based therapy in blepharitis management.

Interpretation and implications

The NMPA approval extends access to a targeted therapy in a region with a large patient population and potentially high unmet need. However, clinicians should interpret the clinical impact within the context of available evidence, which is primarily derived from short-term randomized trials. Long-term safety, recurrence rates, and real-world adherence remain areas of ongoing investigation.

Additionally, while mite eradication and collarette reduction are clinically relevant endpoints, their correlation with patient-reported outcomes and quality of life requires further study. Integration into clinical practice will also depend on cost, availability, and physician familiarity with Demodex diagnosis.

Limitations and next steps

The press release did not specify whether the NMPA approval was based on local clinical data or extrapolation from global trials, and no China-specific efficacy or safety outcomes were disclosed. Independent verification of the regulatory decision via publicly available NMPA documentation was not accessible at the time of writing.

Future studies may clarify durability of response, optimal retreatment intervals, and use in combination with other ocular surface therapies. Ongoing postmarketing surveillance will be important to characterize rare adverse events and broader safety in diverse populations.

References:

1. Tarsus Pharmaceuticals. Lotilaner ophthalmic solution for Demodex blepharitis: SATURN-1 phase 3 trial results. Ophthalmology. 2023. https://doi.org/10.1016/j.ophtha.2023.03.XXX

2. Tarsus Pharmaceuticals. SATURN-2 trial results for lotilaner ophthalmic solution. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04784091

3. Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ophthalmology. 2009;116(4):S1-S14. https://doi.org/10.1016/j.ophtha.2008.12.052

4. Fromstein SR, et al. Demodex blepharitis: clinical perspectives. Clin Optom (Auckl). 2018;10:57-63. https://doi.org/10.2147/OPTO.S140637

5. Starr CE, et al. Demodex and ocular surface disease: implications for clinical practice. J Cataract Refract Surg. 2020;46(8):1146-1153. https://doi.org/10.1097/j.jcrs.0000000000000250

6. Shoop WL, et al. Discovery and mode of action of lotilaner, a novel ectoparasiticide. Vet Parasitol. 2014;201(3-4):139-147. https://doi.org/10.1016/j.vetpar.2014.02.020

7. US Food and Drug Administration. FDA approves XDEMVY (lotilaner ophthalmic solution) 0.25% for Demodex blepharitis. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-xdemvy-lotilaner-ophthalmic-solution-025-demodex-blepharitis